Rockwell Medical (NASDAQ:RMTI), a healthcare company focused on the manufacturing and distribution of life-sustaining hemodialysis products, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
The results underscore a period of significant operational refinement, marked by record-high margins and the company's second consecutive year of adjusted EBITDA profitability.
Net sales for the fourth quarter of 2025 reached $18.3 million, contributing to a full-year revenue total of $69.3 million.
While the company continues to scale its domestic and international distribution of hemodialysis concentrates, the primary narrative of 2025 was the dramatic improvement in underlying unit economics.
Rockwell achieved a gross margin of 21% for the fourth quarter, one of the strongest in the company's history.
This represents a meaningful 600-basis-point improvement over the 15% margin reported in the same period of 2024.
Management attributed this expansion to optimized manufacturing processes, better absorption of fixed costs, and a more favorable product mix within its renal care portfolio.
The company’s focus on fiscal discipline resulted in $2.3 million in positive cash flow from operating activities during the fourth quarter.
This performance strengthened Rockwell's balance sheet, bringing its total cash position to $25 million as of December 31, 2025.
This liquidity provides the firm with a stable foundation to pursue further market share gains among independent and mid-sized dialysis providers.